# Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection

> **NCT02135614** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 189 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infection

## Interventions

- **DRUG:** Presatovir
- **DRUG:** Presatovir placebo

## Key facts

- **NCT ID:** NCT02135614
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-09
- **Primary completion:** 2017-03-27
- **Final completion:** 2017-04-12
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2018-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02135614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02135614, "Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02135614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*